Inhibitors of cyclooxygenase-2: November 1999 - April 2000

Bibliography

• VANE JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature (1971) 231:232–235.
   Web of Science ®Google Scholar
• SMITH JB, WILLIL AL: Aspirin selectively inhibits prosta-glandin production in human platelets. Nature (1971) 231:235–237.
   Web of Science ®Google Scholar
• RAINSFORD KD: Side-effects of anti-inflammatory drugs. Rainsford, Velo (Eds.), MTP Press, Norwell, Massachusetts (1985) 2:343–362.
   Google Scholar
• CLIVE DM, STOFF JS: Renal syndromes associated with non-steroidal anti-inflammatory drugs. N Engl. J. Med. (1984) 310:563–572.
   PubMed Web of Science ®Google Scholar
• PIRSON Y, VAN YPERSELE DE, STRIHOU C: Renal side-effects of non-steroidal anti-inflammatory drugs: clinical relevance. Am. J. Kidney Dis. (1986) 8:337–344.
   Web of Science ®Google Scholar
• ALLISON MC, HOWATSON AG, TORRANCE CJ, LEE FD, RUSSEL RIG: Gastrointestinal damage associated with the use of non-steroidal anti-inflammatory drugs. N Engl. J. Med. (1992) 327:749–754.
   PubMed Web of Science ®Google Scholar
• KUJUBU DA, FLETCHER BS, VARNUM BC, LIN RW, HERSCHMAN HR: T1S10, a phorbol ester tumor promoter-inducible m-RNA from Swill 3T3 cells, encodes a novel prostaglandin synthase/cyclooxyge-nase homologue. J Biol. Chem. (1991) 266:12866–12872.
   PubMed Web of Science ®Google Scholar
• MASFERRER JL, SEIBERT K, ZWEIFEL B, NEEDLEMAN P:Endogenous glucocorticoids regulate an inducible enzyme. Proc. Natl. Acad. Sci. USA (1992) 89:3917–1921.
   PubMed Web of Science ®Google Scholar
• MASFERRER JL, ZWEIFEL B, SEIBERT K, NEEDLEMAN P: Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice. J. Clin. Invest. (1990) 86:1375–1379.
   PubMed Web of Science ®Google Scholar
• HERSCHMAN HR: Review: prostaglandin synthase-2. Biochim. Biophys. Acta. (1996) 1299:125–140.
   PubMed Web of Science ®Google Scholar
• PINTO DJ, PITTS WJ, COPELAND RA, COVINGTON MB, TRZASKOS J, MAGOLDA R: Selective inhibition of cyclooxygenase-2: diaryl heterocycles vs. classical NSAIDs. Med. Chem. Res. (1995) 5:394–398.
   Web of Science ®Google Scholar
• •This paper provides data on the lack of selectivity of current NSAIDs as well as selectivity data on new selective COX-2 series.
   Google Scholar
• SEIBERT K, ZHANG Y, LEAHY K et al.: Pharmacological biochemical demonstration of the role of cyclooxygenase-2 in inflammation and pain. Proc. Natl. Acad. Sci. USA (1994) 91:12013–12017.
   PubMed Web of Science ®Google Scholar
• ••This paper provides key basic research data in support ofuse of selective COX-2 to provide the positive effects of pain and inflammation relief associated with non-selective COX inhibitors.
   Google Scholar
• MASFERRER JL, ZWEIFEL BS, MANNING PT et al.: Selective of inducible cyclooxygenase-2 in vivo is anti-inflammatory and nonulcerogenic. Proc. Natl. Acad. Sci. USA (1994) 91:3228–3232.
   PubMed Web of Science ®Google Scholar
• ••This paper provides evidence that selective COX-2 inhibi-tors are anti-inflammatory without displaying the GI side effect profile common to all NSAIDs.
   Google Scholar
• KALGUTKAR AS: Selective cyclooxygenase-2 inhibitors non-ulcerogenic anti-inflammatory agents. Exp. Opin. Ther. Patents (1999) 9(7):831–849.
   Web of Science ®Google Scholar
• ••This previous review provides an excellent resource to theearlier patent literature.
   Google Scholar
• CARTER JS: Recently reported inhibitors of cyclooxygenase-2. Exp. Opin. Ther. Patents (1998) 8(1):21–29.
   Web of Science ®Google Scholar
• TALLEY JJ: Selective inhibitors of cyclooxygenase-2. Exp. Opin. Ther. Patents (1997) 7(0:55–62.
   Web of Science ®Google Scholar
• PEPTIBOON P, RIENDEAU D: Selective Cyclo-oxygenase-2 inhibitors. Annual Rep. in Merl. Chem. Academic Press (1997) 32:211–220.
   Web of Science ®Google Scholar
• FUTAKI N, TAKAHASHI S, YODOYAMA M et al.: NS-398, anew anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. Prostaglandins (1994) 47:55–59.
   PubMed Web of Science ®Google Scholar
• •This discovery of NS-398 as a selective COX-2 inhibitor is one of the landmark events in the development of selective COX-2 inhibitors. The work presented led to the discovery of many similar selective COX-2 agents.
   Google Scholar
• RABASSEDA X: Nimesulide: a selective cyclooxygenase-2 inhibitor anti-inflammatory drug. Drugs Today (1996) 2:365–384.
   Google Scholar
• WIESENBERG-BOTTCHER I, SCHWEIZER A, GREEN JR, SELTENMEYER Y, MULLER K: The pharmacological profile of CGP 28238, a highly potent inflammatory compound. Agents Actions (1989) 26:240–242.
   PubMedGoogle Scholar
• CHAN CC, BLACK C, BOYCE S et al: Pharmacology of a cyclooxygenase-2 inhibitor L-745,337: a novel non-steroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and primate stomach. J. Pharmacol Exp. Ther. (1995) 274:1531–1537.
   PubMed Web of Science ®Google Scholar
• •This paper describes the optimisation approach used by Merck Frosst to develop one of the series of selective COX-2 inhibitors.
   Google Scholar
• GANS KR, GALBRAITH W, ROMAN RJ et al.:-inflammatory and safety profile of DuP 697, a novel orally effective prostaglandin synthesis inhibitor. J. Pharmacol. Exp. Ther. (1990) 254:180–187.
   PubMed Web of Science ®Google Scholar
• ••This paper describes the impressive safety and efficacyprofile of DuP 697, which was to become probably the most important lead in the search for a selective COX-2 inhibitor.
   Google Scholar
• PENNING TD, TALLEY JJ, BERTENSHAW SR et al: Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase inhibitors: Identification of 445-(4-methylpheny0-3-(trifluoro-methyl) -H -pyraz o 1-1 -yl] be nz ene- sulfonamide (SC-58635, celecoxib). J. Med. Chem. (1997) 40:1347–1365.
   PubMed Web of Science ®Google Scholar
• •This paper provides detailed SAR and early PK data leading to the discovery and development of celecoxib, one of the selective COX-2 inhibitors currently in clinical trials.
   Google Scholar
• SIMON LS, WEAVER AL, GRAHAN DY et al.-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA (1999) 282(20) 1921–1928
   PubMed Web of Science ®Google Scholar
• GOLDENBERG MM: Celecoxib, a selective cyclooxygenase-2 inhibitor for the treatment of rheumatoid arthritis and osteoarthritis. Clin. Ther. (1999) 21 (9) :1497–1513.
   PubMed Web of Science ®Google Scholar
• SIMON LS, LANZA FL, LIPSKY PE et al.: Preliminary studyof the safety and efficacy of SC-58635, a novel cyclooxygenase-2 inhibitor. Arthritis Rheum. (1998) 41(9):1591–1602.
   PubMed Web of Science ®Google Scholar
• EHRICH EW, SCHNITZER TJ, MCILWAIN H, et al. Effect of COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib. j Rheumatol. (1999) 26(11):2438–2447.
   PubMed Web of Science ®Google Scholar
• MORRISON BW, CHRISTENSEN S, YUAN W et al.: Analgesic efficacy of the cyclooxygenase-2-specific inhibitor rofecoxib in post-dental surgery pain: a randomized, controlled trial. Clin. Ther. (1999) 21(6):943–953.
   PubMed Web of Science ®Google Scholar
• EHRICH EW, DALLOB A, DE LEPELEIRE I et al.: Characteri-zation of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model. Clin. Pharmacol. Ther. (1999) 65:336–347.
   Google Scholar
• Novel COX-2 inhibitors. Exp. Opin Ther. Patents (1995)5 (4):357–359.
   Google Scholar
• MATSUSHITA M, MASAKI M, YAGI Y et al.: Pharma-cological profile of JTE-522, a novel prostaglandin H synthase-2 inhibitor, in rats. Inflamm. Res. (1997) 46:461–466.
   PubMed Web of Science ®Google Scholar
• TALLEY JJ, BROWN DE, CARTER JS et al.: 4-[5-Methyl-3-pheny1isoxaz01-4-yl]benzenesulfonamide, valdecoxib: a potent and selective inhibitor of cox-2. J. Med. Chem. (2000) 43(5):775–777.
   PubMed Web of Science ®Google Scholar
• KURUMBAIL RG, STEVENS AM, GIERSE JK et al: Structuralbasis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature (1996) 384:644–648.
   PubMed Web of Science ®Google Scholar
• •This paper provides an informative overview of the x-ray data for COX-2 and inhibitor-COX-2 complexes and insight into some of the differences between COX-1 and -2 based upon single amino acid residue changes.
   Google Scholar
• RIENDEAU D, PERCIVAL MD, BOYCE S, BRIDEAU C et al.: and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor. Br. J. Pharm. (1997) 121:105–117.
   PubMed Web of Science ®Google Scholar
• ••This paper provides a definitive study of the nature ofselective inhibition of COX-2 by 'DFU' and its slow reversi-bility. In addition, this paper discloses some of the variation in assay conditions which provide different COX selectivity.
   Google Scholar
• REITZ DB, LID, NORTON MB et al: Selective cyclooxyge-nase inhibitors: novel 1,2-diarylcyclopentenes are potent and orally active COX-2 inhibitors. J. Med. Chem. (1994) 37:3878–3881.
   PubMed Web of Science ®Google Scholar
• SMITH CJ, ZHANG Y, KOBOLDT CM et al.: Pharma-cological analysis of cyclooxygenase-1 in inflamma-tion. Proc. Natl. Acad. ScL USA 95:13313–13318.
   Google Scholar
• WOODS KW, MCCROSKEY RW, MICHAELIDES MR, WADACK, HULKOWER KI, BELL RL: The design and synthesis of novel cyclooxygenase-2 inhibitors. 214th ACS National Meeting. Las Vegas NV, USA (7–11 September 1997) Poster Medi 92.
   Google Scholar
• BLACK WC, BAYLY C, BELLEY M et al: From indometha-cin to a selective COX-2 inhibitor: development of indolalkanoic acids as potent and selective cyclooxygenase-2 inhibitors. Bioorg. Med. Chem. Lett. (1996) 6(6)725–730.
   Google Scholar
• •This paper describes the conversion of one of the most efficaceous NSAIDs into a selective COX-2 inhibitor.
   Google Scholar
• GIERSE JK, KOBOLDT CM, WALKER MC et al.: Kineticbasis for selective inhibition of cyclo-oxygenases. Biochem. J. (1999) 339(3):607–614.
   PubMedGoogle Scholar
• OULLET M, PERCIVAL MD: Effect of inhibitor time-dependency on selectivity towards cyclooxyge-nase isoforms. Biochem. J. (1995) 305:247–251.
   Google Scholar
• ••This paper provides kinetic data on the nature of selectiveCOX-2 inhibition and its slow reversibility.
   Google Scholar
• COPELAND RA, WILLIAMS JM, GIANNARAS J: Mechanism selective inhibition of the inducible isoform of prostaglandin G/H synthase. Proc. Natl. Acad. ScL USA (1994) 91:11202–11206.
   PubMed Web of Science ®Google Scholar
• ••This paper provides the earliest reported data explaining thenature of 'irreversible' inhibition of COX-2.
   Google Scholar
• LANZO CA, SUTIN J, ROWLINSON S et al.: Fluorescence analysis of the association and dissociation of a diarylheterocycle to cyclooxygenase-1 and cyclooxygenase-2: dynamic basis of cyclooxygenase-2 selectitity. Biochemistry (2000)39:6228–6234.
   PubMed Web of Science ®Google Scholar
• KIEFER JR, PAWLITZ JL, MORELAND KT et al: Structural insights into the stereochemistry of the cyclooxyge-nase reaction. (2000) 405:97–101.
   Google Scholar
• GIERSE JK, MCDONALD JJ, HAUSER SD et al.: A single animo acid difference between cyclooxygenase-1 (COX-1) and -2 (COX-2) reverses the selectivity of COX-2 specific inhibitors. J. Biol. Chem. (1996) 271(26):15810–15814.
   PubMed Web of Science ®Google Scholar
• LI C-S, BRIDEAU C, CHAN CC et al: Pyridazinones as selective cyclooxygenase-2 inhibitors. Book of Abstracts. 216th ACS National Meeting. Boston, USA (23–27 August 1998) MEDI–032.
   Google Scholar
• RICKETTS AP, LUNDY KM, SEIBEL SB et al.: Evaluation of selective inhibition of canine cyclooxygenase 1 and 2 by carprofen and other nonsteroidal anti-inflammatory drugs. Am. J. Vet. Res. (1998) 59(10:1441–1446.
   PubMedGoogle Scholar
• REDDY BS, HIROSE Y, LUBET R et al.: Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res. (2000) 60(2)293–297.
   Google Scholar
• KOKI AT, LEAHY KM, MASFERRER JL.: Potential utility of COX-2 inhibitors in chemoprevention and chemotherapy. Exp. Opin. Invest. Drugs (1999) 8(10):1623–1638.
   Google Scholar
• •This review details the theory and data supporting the study of COX-2 inhibitors in oncology.
   Google Scholar
• HARRIS RE, ALSHAFIE GA, ABOU-ISSA H, SEIBERT K.: Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res. (2000) 60(8):2101–2103.
   Google Scholar
• WILLIAMS CS, SHATTUCK-BRANDT RL, DUBOIS RN: The role of COX-2 in intestinal cancer. Exp. Opin. Invest. Drugs (1999) 8(0:1–12.
   PubMedGoogle Scholar
• •This review details the theory and data supporting the study of COX-2 inhibitors in oncology.
   Google Scholar
• FOSSLIEN E: Molecular pathology of cyclooxygenase-2 in neoplasia. Annals Clin. Lab. Sci. (2000) 30(1):3–21.
   PubMed Web of Science ®Google Scholar
• MASFERRER JL, LEAHY KM, KOKI AT et al.: Antiangio-genic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. (2000) 60(5) :1306–1311.
   PubMed Web of Science ®Google Scholar
• KISHI K, PETERSEN S, PETERSEN C et al: Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor. Cancer Res. (2000) 60(5) :1326–1331.
   PubMed Web of Science ®Google Scholar
• NAKAYAMA M, UCHIMURA K, ZHU RL et al.: Cyclooxygenase-2 inhibition prevents delayed death of CA1 hippocampal neurons following global ischemia. Proc. Natl. Acad. Sci. (1998) 95:10954–10959.
   PubMed Web of Science ®Google Scholar
• CHEN J, MARSH T, ZHANG JS, GRAHAN SH: Expressionof cyclooxygenase 2 in rat brain following kainate treatment. NeuroReport (1995) 6:245–248.
   PubMed Web of Science ®Google Scholar
• O'BANION MK: COX-2 and Alzheimer's disease:potential roles in inflammation and neurodegenera-tion. Exp. Opin. Invest. Drugs (1999) 8(10:1521–1536.
   PubMedGoogle Scholar
• •This review details the theory and data supporting the study of COX-2 inhibitors in treatment of neurodegenerative diseases.
   Google Scholar